FOXO4-DRI
Senolytic peptide (D-retro-inverso FOXO4 fragment)
A designed senolytic peptide studied for selective clearance of senescent cells.
How it works
Disrupts the FOXO4 and p53 interaction that keeps senescent cells alive, releasing p53 to the mitochondria and triggering apoptosis in those cells specifically.
What research has shown
Aged mouse studies report restored fitness, fur density and renal function after intermittent administration. No human trials are published.
Reported ranges in the literature
Low end
Animal model doses only
Optimal
No established human range
High end
Not characterized in humans
Frequency reported in the literature: Intermittent pulses in reported animal protocols. Note: Preclinical senolytic. Human safety data does not exist.
Protocol duration and pairing
Typical study duration
Short 3 to 5 day pulses repeated over several weeks in senolytic models.
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.